drugset / Trial / NCT02410356

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

NCT02410356

Phase 3 Terminated 34 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.

Timeline

Start
2015-04-30
Primary completion
2016-02-29
Completion
2016-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ALBUSOMATROPIN Protein / enzyme biologic Other
Comparator dGH Unknown Other

Indications